Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8(+) T Cell Responses via CD169(+) Macrophages and cDC1

Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should therefore comprise a potent antigen and adjuvant. Antigen targeting to splenic CD169(+) macrophages was shown to induce robust CD8(+) T cell responses via antigen transfer to cDC1. Interestingly, CD169(+) macr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Vaccines (Basel)
Auteurs principaux: Grabowska, Joanna, Stolk, Dorian A., Nijen Twilhaar, Maarten K., Ambrosini, Martino, Storm, Gert, van der Vliet, Hans J., de Gruijl, Tanja D., van Kooyk, Yvette, den Haan, Joke M.M.
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7830461/
https://ncbi.nlm.nih.gov/pubmed/33467048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines9010056
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires